Archives
-
Paroxetine in Colon Cancer: MET and ERBB3
2026-10-05
Jang and colleagues investigated whether the established antidepressant paroxetine could be repositioned against colorectal cancer, linking reduced tumor-cell growth to MET and ERBB3-associated signaling changes. The study provides promising preclinical evidence across cell, spheroid, and xenograft models, but it does not establish clinical efficacy or definitive direct target engagement.
-
CD44 Metabolic Rewiring in IDH-Mutant Leukemia
2026-10-05
The reference study identifies CD44-driven metabolic rewiring as a dependency that helps IDH-mutant leukemia sustain NADPH production and R-2HG synthesis. Its findings support a conceptual combination strategy in which mutant IDH inhibition is paired with disruption of CD44-associated metabolism, while remaining preclinical and model-dependent.
-
MRTFA–KCNMB1 Control of Cancer Cell Stiffness
2026-10-04
The reference study identifies potassium efflux and the BK-channel auxiliary subunit KCNMB1 as regulators of cancer-cell stiffness downstream of MRTFA. Its findings connect ionic control of cell mechanics with immune escape and metastatic colonization, while also showing that the same perturbation can have contrasting effects in nonmalignant pericytes.
-
HOXC8, Caspase-1, and Lung Tumor Pyroptosis
2026-10-03
A 2025 study identifies HOXC8 as a transcriptional brake on CASP1 expression in non-small cell lung cancer, linking HOXC8 loss to caspase-1-dependent pyroptotic cell death. Its central innovation is the proposed HOXC8–HDAC1/2 regulatory axis, which connects transcriptional control with tumor-cell survival and suggests a context-dependent role for pyroptosis in cancer biology.
-
Ferroptosis Signature and Atorvastatin in HCC
2026-10-02
A 2025 study combined ferroptosis-related transcriptomics, survival modeling, Connectivity Map screening, and experimental validation to develop a four-gene prognostic signature for hepatocellular carcinoma. The work also identified Atorvastatin as a candidate ferroptosis-inducing agent that inhibited HCC cell growth and migration in cellular and animal models, while highlighting the need for further mechanistic and clinical validation.
-
Ginsenoside Rg1: From Neuroimmune Signal to Strategy
2026-10-01
A translational perspective on how Ginsenoside Rg1 connects gut barrier integrity, regulatory T cells, inflammation, and synaptic function in anesthesia-related neuroimmune disruption—and how researchers can turn that mechanism into a rigorous experimental strategy.
-
Bardoxolone Methyl: Redox Context for Assays
2026-10-01
Bardoxolone methyl and CDDO methyl ester offer a powerful way to study Nrf2 activation, NF-kB inhibition, and redox adaptation. This article connects those mechanisms to thioredoxin-controlled replication stress and shows how to design more informative kidney and oncology assays.
-
Ginsenoside Rg1: From Axis Biology to Assay Design
2026-09-30
Ginsenoside Rg1 is a Panax-derived triterpene saponin with emerging relevance to neuroprotection research. This article translates recent gut–immune–brain findings into practical assay decisions while clarifying chemical handling, causal interpretation, and model limitations.
-
From Cap Chemistry to mRNA Vaccine Translation
2026-09-30
Translation-ready mRNA is shaped by more than coding sequence design. This thought-leadership article connects ARCA co-transcriptional capping, template-encoded poly(A) tails, and nanovaccine performance to practical decisions in RNA vaccine development, in vitro translation, and translational workflow design.
-
Ginsenoside Rg1 in Neuroimmune Research
2026-09-29
Ginsenoside Rg1 provides a practical way to connect behavioral, synaptic, inflammatory, and gut-barrier readouts in anesthesia-related neuroprotection research. This workflow translates a Treg-dependent reference finding into reproducible compound handling, assay selection, and troubleshooting strategies.
-
D-Luciferin Workflows for Glioblastoma Studies
2026-09-29
D-Luciferin enables sensitive firefly luciferase readouts for promoter activity, intracellular ATP quantification, and non-invasive tumor burden assessment. This workflow guide shows how to connect those measurements with targeted glioblastoma research while separating reporter signal from true therapeutic response.
-
ALC-0159 in mRNA Lipid Nanoparticles
2026-09-28
ALC-0159 is a PEG-conjugated lipid excipient for mRNA lipid nanoparticle formulations. Current MeDZ evidence supports a separate charge-switching strategy in mice, not a direct efficacy claim for ALC-0159.
-
MARCH5 Drives Mitochondria-Derived Pre-peroxisomes
2026-09-28
Zheng and colleagues identify the mitochondrial ubiquitin ligase MARCH5 as a selective regulator of PEX3-containing vesicle formation, an early step in mitochondria-supported peroxisome biogenesis. Their findings distinguish this pathway from other mitochondria-derived vesicles and provide a framework for investigating how cells maintain peroxisome homeostasis.
-
Mildronate Lipidoids Reduce Inflammation in mRNA Vaccines
2026-09-27
A 2024 ACS Nano study reports mLNP-69, a lipid nanoparticle built with a low dose of mildronate-derived cationic lipid, as a way to retain mRNA delivery while reducing local inflammation compared with an SM-102-based formulation. In prophylactic and therapeutic B16OVA melanoma models, the formulation supported antitumor vaccine activity, offering a preclinical strategy for balancing delivery performance and carrier-associated inflammation.
-
TXA–SNAP–Propolis Dressings for Rapid Hemostasis
2026-09-26
Nguyen and colleagues developed a bilayer wound dressing that pairs tranexamic acid and propolis at the wound-facing surface with an NO-releasing SNAP layer. Laboratory assays showed an early clot-associated response and substantial reductions in bacterial colony counts, supporting further study of combined hemostatic and antimicrobial dressings—not yet establishing clinical efficacy.